Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of testing for microsatellite instability-high (MSI-H) status in patients with gastric cancers.
Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of testing for microsatellite instability-high (MSI-H) status in patients with gastric cancers.
While MSI-H is a rare subset of gastric cancers, it is important to determine MSI status early on in treatment. Patients with MSI-H tumors can have a life-changing response to immune checkpoint inhibitors, says Janjigian.
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More